论文信息 - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL) - 字舞流文

Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)

P. Ascierto | H. Schmidt | L. Bastholt | C. Garbe | P. Rutkowski | J. Grob | V. Chiarion-Sileni | M. Maio | C. Lebbé | B. Dréno | C. McNeil | C. Robert | C. Loquai | A. Mackiewicz | O. Hamid | L. Thomas | D. Hennicken | M. Vecchio | A. Qureshi | A. Fernandez